Shen K P, Lin R J, Lin C Y, Chiang L C, Lai W T, Cheng C J, Chen I J, Wu B N
Department of Pharmacology, College of Medicine, Kaohsiung Medical University, 100 Shin-Chuan 1st Road, Kaohsiung 807, Taiwan.
Gen Pharmacol. 2000 Jul;35(1):47-57. doi: 10.1016/s0306-3623(01)00090-8.
KMCP-98 is a newly synthesized adenosine receptor agonist by alkylation at the 7-position of the xanthines nucleus. We first investigated the pharmacological activities of KMCP-98 under in vivo and in vitro conditions. Acute intravenous injection of KMCP-98 (1.0, 2.0 and 3.0 mg/kg) produced a temporary fall in blood pressure and heart rate, followed by a sustained fall in heart rate in pentobarbital-anesthetized Wistar rats. The hypotensive and bradycardiac responses were inhibited by pretreatment with an A(1) adenosine receptor antagonist 8-phenyltheophylline (8-PT, 0.5 mg/kg). Both KMCP-98 and adenosine (0.3-100 microM) produced negative inotropic activity in isolated guinea pig left atria. The negative inotropic activity of KMCP-98 was significantly blocked by pretreatment with A(1) receptor antagonists 8-PT (10 microM) and xanthine amine congener (XAC, 10 microM), a nonselective adenosine antagonist theophylline (10 microM), a K(+) channel blocker tetraethylammonium (TEA, 10 mM) and a K(ATP) channel blocker glibenclamide (1 microM). KMCP-98 (0.03-30 microM) produced concentration-dependent relaxations in carbachol (1 microM) precontracted guinea pig tracheal smooth muscle. The trachea relaxant response of KMCP-98 was markedly inhibited by A(2), A(2a) and A(2b) adenosine receptor antagonists 3,7-dimethyl-1-propargylxanthine (DMPX, 10 microM), 8-(3-chlorostyryl)caffeine (CSC, 10 microM) and alloxazine (10 microM), respectively, the nitric oxide synthase (NOS) inhibitor L-NAME (100 microM) and also by TEA and glibenclamide. In addition, KMCP-98 (0.03-30 microM) elicited relaxant response in norepinephrine (3 microM) precontracted rat thoracic aorta in a concentration-dependent manner. The thoracic aorta relaxant response of KMCP-98 was also significantly inhibited by DMPX, CSC, alloxazine, L-NAME, TEA and glibenclamide. Furthermore, the binding characteristics of KMCP-98, adenosine and 5'-N-ethylcarboxaminoadenosine (NECA) were evaluated in [(3)H]DPCPX and [(3)H]CGS 21680 binding to rat cortex and striatum, respectively. The K(i) values of KMCP-98 for predominate A(1) and A(2) adenosine receptor sites were 3908+/-952 and 158+/-10 nM, respectively. In conclusion, KMCP-98 was found to be a xanthine-based adenosine receptor agonist associated cardiac depression, tracheal and aortic smooth muscle relaxations.
KMCP - 98是一种通过对黄嘌呤核7位进行烷基化新合成的腺苷受体激动剂。我们首先在体内和体外条件下研究了KMCP - 98的药理活性。在戊巴比妥麻醉的Wistar大鼠中,急性静脉注射KMCP - 98(1.0、2.0和3.0mg/kg)导致血压和心率暂时下降,随后心率持续下降。A(1)腺苷受体拮抗剂8 - 苯基茶碱(8 - PT,0.5mg/kg)预处理可抑制降压和心动过缓反应。KMCP - 98和腺苷(0.3 - 100μM)在离体豚鼠左心房均产生负性肌力作用。A(1)受体拮抗剂8 - PT(10μM)、黄嘌呤胺类似物(XAC,10μM)、非选择性腺苷拮抗剂茶碱(10μM)、钾通道阻滞剂四乙铵(TEA,10mM)和钾ATP通道阻滞剂格列本脲(1μM)预处理可显著阻断KMCP - 98的负性肌力作用。KMCP - 98(0.03 - 30μM)使卡巴胆碱(1μM)预收缩的豚鼠气管平滑肌产生浓度依赖性舒张。KMCP - 98的气管舒张反应分别被A(2)、A(2a)和A(2b)腺苷受体拮抗剂3,7 - 二甲基 - 1 - 炔丙基黄嘌呤(DMPX,10μM)、8 - (3 - 氯苯乙烯基)咖啡因(CSC,10μM)和咯嗪(10μM)、一氧化氮合酶(NOS)抑制剂L - NAME(100μM)以及TEA和格列本脲显著抑制。此外,KMCP - 98(0.03 - 30μM)使去甲肾上腺素(3μM)预收缩的大鼠胸主动脉产生浓度依赖性舒张反应。KMCP - 98的胸主动脉舒张反应也被DMPX、CSC、咯嗪、L - NAME、TEA和格列本脲显著抑制。此外,分别在[(3)H]DPCPX和[(3)H]CGS 21680与大鼠皮质和纹状体的结合实验中评估了KMCP - 98、腺苷和5'-N - 乙基羧基氨基腺苷(NECA)的结合特性。KMCP - 98对主要的A(1)和A(2)腺苷受体位点的K(i)值分别为3908±952和158±10nM。总之,发现KMCP - 98是一种基于黄嘌呤的腺苷受体激动剂,与心脏抑制、气管和主动脉平滑肌舒张有关。